Compare Amylx Pharmaceuticals Inc (AMLX) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs T Rowe Price Group Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while T Rowe Price Group Inc trades at $118.55 (market cap $25.40B). The key difference: T Rowe Price Group Inc is far larger — about 12.8× Amylx Pharmaceuticals Inc's market cap, and T Rowe Price Group Inc pays a 4.39% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | TROW | |
|---|---|---|
Market Cap | $1.98B | $25.40B |
Sector | Health | Financials |
52-Week High | $18.70 | $120.16 |
52-Week Low | $7.64 | $86.19 |
Enterprise Value | $1.70B | $22.11B |
Dividend Yield | — | 4.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
T. Rowe Price (TROW) trades at $118.55, up 1.28% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 28.28% net income margin and a P/E of 12.72, indicating potential undervaluation. Recent earnings have mostly beaten expectations, and the company maintains robust cash flow, supporting a sustainable dividend. Strategic enhancements to its institutional business and positive media coverage highlight ongoing growth initiatives.
The outlook for TROW is positive, driven by solid fundamentals and strategic positioning, though investor caution is warranted given the majority hold rating from analysts and competitive pressures in asset management. Upside potential exists if the company continues to exceed earnings estimates and manage equity outflows effectively, but macroeconomic volatility remains a key risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
